Anticancer effect of terpenes: focus on malignant melanoma

• Published in: Pharmacological reports Vol. 75; no. 5; p. 1115
• Main Authors: Wróblewska-Łuczka, Paula, Cabaj, Justyna, Bargieł, Julia, Łuszczki, Jarogniew J
• Format: Journal Article
• Language: English
• Published: Switzerland 01-10-2023
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Humans; Limonene; Melanoma - drug therapy; Melanoma, Cutaneous Malignant; Skin Neoplasms - drug therapy; Terpenes - pharmacology; Terpenes - therapeutic use; Anticancer therapy; Terpenes; Melanoma
• ISSN: 2299-5684
• DOI: 10.1007/s43440-023-00512-1

Melanoma is a highly aggressive and life-threatening form of skin cancer that accounts for a significant proportion of cancer-related deaths worldwide. Although conventional cancer therapies, such as surgical excision, chemotherapy, and radiation, have been used to treat malignant melanoma, their efficacy is often limited due to the development of resistance and adverse side effects. Therefore, there is a growing interest in developing alternative treatment options for melanoma that are more effective and less toxic. Terpenes, a diverse group of naturally occurring compounds of plant origin, have emerged as potential anticancer agents due to their ability to inhibit tumor growth and induce apoptosis in cancer cells. In this review, the current understanding of the anticancer effects of terpenes (including, thymoquinone, β-elemene, carvacrol, limonene, α-pinene, β-caryophyllene, perillyl alcohol, taxol, betulinic acid, α-bisabolol, ursolic acid, linalool, lupeol, and artesunate) was summarized, with a special focus on their potential as therapeutic agents for malignant melanoma.